Shortcomings in the technical documentation of mesh implants intended to treat pelvic organ prolapse used in the Netherlands After a detailed assessment of the technical documentation of 9 different mesh implants intended to treat pelvic organ prolapse used in NL (2018) RIVM concludes that the safety and performance of these products were not properly substantiated.
Better monitoring of RSV thanks to new European project RIVM and Nivel contribute to building a European RSV monitoring network. Through the network, European health institutions and laboratories will exchange data on the spread of RSV. This will help us to better monitor the virus.
Call for global action plan to save our oceans Scientists involved in the Seas Oceans and Public Health In Europe (SOPHIE) Project have proposed the first steps towards a united global plan to save our oceans, for the sake of human health. Andrzej-kryszpiniuk
More reports of adverse effects of implants in 2019 In 2019, the Dutch reporting centre for adverse effects of medical implants (MEBI) received 397 reports of suspected adverse effects. The reports concerned 462 implants.
Mesh implants intended to treat pelvic organ prolapse Synthetic mesh are used to treat patients with pelvic organ prolapse.
Graphit rain poses health risk An assessment of potential health risks shows that graphite rain contains heavy metals and PAHs.
Young people who use screens before sleeping have more sleep problems Young people (13-18 years) who use light-emitting screens daily in the hour before going to sleep have more sleep problems.
Summary International Expert Meeting on breast implant-associated lymphoma On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.